BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
April 27, 2015 09:42 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., April 27, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced completion of the rolling submission of a New Drug Application (NDA) to the United...
BioMarin Presents Data on Duchenne Muscular Dystrophy at the 67th American Academy of Neurology Annual Meeting
April 23, 2015 16:51 ET
|
BioMarin Pharmaceutical Inc.
Interim analysis of prospective natural history increases understanding of Duchenne muscular dystrophy
BioMarin to present data from seven abstracts on Duchenne and Huntington's disease at AAN...
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 21, 2015 16:10 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., April 21, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on April 15, 2015, the compensation committee of BioMarin's board of directors...
BioMarin to Host First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, April 30 at 4:30pm ET
April 14, 2015 08:00 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a...
BioMarin Announces One Oral and 7 Poster Presentations at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
March 30, 2015 09:00 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., March 30, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the results of a post-hoc sub-analysis of the PKU-016 or ASCEND study, the largest...
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
March 18, 2015 08:00 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., March 18, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on March 16, 2015, the compensation committee of BioMarin's board of directors...
BioMarin Announces Fourth Quarter and Full Year 2014 Financial Results
February 25, 2015 16:01 ET
|
BioMarin Pharmaceutical Inc.
Total BioMarin Revenue Increased 37% to $751 million in 2014
Rolling Submission of NDA for Drisapersen Underway; Acquisition of Prosensa Complete
Financial Highlights ($ in millions, except per...
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 20, 2015 16:15 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Feb. 20, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on February 17, 2015, the compensation committee of BioMarin's board of directors...
Prosensa Announces Voluntary Delisting and Advance Liquidation Distribution
February 10, 2015 12:16 ET
|
BioMarin Pharmaceutical Inc.
LEIDEN, The Netherlands, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA) ("Prosensa" or the "Company"), the biopharmaceutical company focusing on RNA-modulating therapeutics for...
BioMarin Announces 2 Oral and 8 Poster Presentations at Lysosomal Disease Network's 11th Annual WORLD Symposium(TM)
February 09, 2015 08:00 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Feb. 9, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the company would make two data presenations in addition to presenting eight...